This brand name is authorized in United States.
The drug FOUNDAYO contains one active pharmaceutical ingredient (API):
1
|
UNII
7ZW40D021M - ORFORGLIPRON
|
|
Orforglipron is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| FOUNDAYO Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 0002-4178, 0002-4503, 0002-4794, 0002-4803, 0002-4839, 0002-4953 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.